



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2153068 C 2007/05/01

(11)(21) **2 153 068**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 1993/12/08
(87) Date publication PCT/PCT Publication Date: 1994/07/21
(45) Date de délivrance/Issue Date: 2007/05/01
(85) Entrée phase nationale/National Entry: 1995/06/29
(86) N° demande PCT/PCT Application No.: US 1993/011915
(87) N° publication PCT/PCT Publication No.: 1994/016057
(30) Priorité/Priority: 1992/12/31 (US999,742)

(51) Cl.Int./Int.Cl. *C12N 15/85* (2006.01),
A01K 67/027 (2006.01), *A61K 31/70* (2006.01),
A61K 48/00 (2006.01), *C12N 15/11* (2006.01)

(72) Inventeurs/Inventors:
KUFE, DONALD, US;
ABE, MIYAKO, US

(73) Propriétaire/Owner:
DANA-FARBER CANCER INSTITUTE, INC., US

(74) Agent: KIRBY EADES GALE BAKER

(54) Titre : SEQUENCE STIMULATRICE POUR LA MODULATION DE L'EXPRESSION DANS LES CELLULES
EPITHELIALES

(54) Title: ENHANCER SEQUENCE FOR MODULATING EXPRESSION IN EPITHELIAL CELLS

(57) **Abrégé/Abstract:**

Isolated DNA encompassing the DF3 enhancer as well as a sequence encoding a heterologous polypeptide provides epithelial tissue-selective gene expression of the heterologous polypeptide, useful in methods of therapy.



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

2153068



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 5/00, 15/11, 15/85, C12P 21/02	A1	(11) International Publication Number: WO 94/16057 (43) International Publication Date: 21 July 1994 (21.07.94)
(21) International Application Number: PCT/US93/11915 (22) International Filing Date: 8 December 1993 (08.12.93) (30) Priority Data: 07/999,742 31 December 1992 (31.12.92) US (71) Applicant: DANA-FARBER CANCER INSTITUTE, INC. [US/US]; 44 Binney Street, Boston, MA 02110-2804 (US). (72) Inventors: KUFÉ, Donald; 179 Grove Street, Wellesley, MA 02181 (US). ABE, Miyako; 400 Brookline Avenue, Apartment 24C, Boston, MA 02115 (US). (74) Agent: FRASER, Janis, K.; Fish & Richardson, 225 Franklin Street, Boston, MA 02110-2804 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: ENHANCER SEQUENCE FOR MODULATING EXPRESSION IN EPITHELIAL CELLS (57) Abstract Isolated DNA encompassing the DF3 enhancer as well as a sequence encoding a heterologous polypeptide provides epithelial tissue-selective gene expression of the heterologous polypeptide, useful in methods of therapy.		

- 1 -

ENHANCER SEQUENCE FOR MODULATING EXPRESSION
IN EPITHELIAL CELLS

Statement as to Federally Sponsored Research

5 The work described herein was supported in part by
United States Public Health Service Grant CA-38879 from
the National Cancer Institute, and by a grant from the
Department of Health and Human Services. The United
States Government therefore has certain rights in the
10 invention.

The invention relates to tissue-specific enhancer
DNA sequences, which modulate the expression of
downstream sequences in eukaryotic cells.

Background of the Invention

15 Epithelium is the tissue that covers and lines the
free surfaces of the body, and includes cells of the skin
and sensory organs, as well as the specialized cells
lining the blood vessels, gastrointestinal tract, air
passages, ducts of the kidneys and endocrine organs.
20 Epithelial cells maintain many diverse and essential
cellular functions, including synthesizing and secreting
proteins and other products, providing barriers, and
proliferating to replace constantly eroded surface
epithelia. Carcinomas, which are cancers derived from
25 epithelial cells, account for the majority of malignant
neoplasias, including most cancers of the breast, lung,
colon, prostate, ovary, and pancreas.

2153068

- 2 -

The so-called DF3 gene encodes a high molecular weight glycoprotein which is aberrantly expressed by malignant human epithelia of various types. The DF3 glycoprotein is a member of a family of related

5 carcinoma-associated antigens with core proteins ranging from 160 to 230 kD (Abe et al., J. Immunol. 139:257-261, 1987; Abe et al., Cancer Res. 49:2834-2839, 1989). This antigen is expressed on the apical borders of secretory mammary epithelium and at high levels in the cytosol of

10 less differentiated malignant cells (Kufe et al., Hybridoma 3:223-232, 1984). DF3 antigen expression correlates with the degree of breast tumor differentiation (Lundy et al., Breast Cancer Res. Treat. 5:269-276, 1985). Moreover, the detection of this

15 antigen in human milk (Abe et al., Cancer Res. 44:4574-4577, 1984) has suggested that its expression represents a differentiated function of normal mammary cells.

Previous studies have demonstrated that the DF3 gene is highly over-expressed in human breast

20 carcinomas and that expression of this gene is regulated at the transcriptional level (Kufe et al., Hybridoma 3:223-232, 1984; Abe et al., J. Cell. Physiol. 143:226-231, 1990).

Summary of the Invention

25 Applicants have determined that the regulatory sequences for the DF3 gene, which is selectively expressed only in epithelial cells, are located in the 5'-flanking region of this gene; that a novel cis-acting

- 3 -

enhancer sequence functions to control transcription in cells expressing this gene; and that this enhancer can be linked to a heterologous coding sequence to increase tissue-specific expression of that coding sequence in
5 epithelium, and particularly in carcinoma cells.

As disclosed herein, the DF3 enhancer has been cloned and sequenced. By DF3 enhancer is meant either the sequence of SEQ ID NO:2, or a fragment thereof with enhancer activity. In preferred embodiments, the
10 enhancer of the invention includes a sequence substantially identical to SEQ ID NO:1. In other preferred embodiments, the sequence is substantially identical to either the first 11 base pairs (SEQ ID NO:3) or the last 21 base pairs (SEQ ID NO:4) of SEQ ID NO:1.
15 Enhancer activity can be determined by inserting the sequence to be evaluated into a chloramphenicol acetyltransferase (CAT) expression vector, transiently transfecting appropriate cells with the vector, and measuring CAT activity in the cells. Fragments which
20 have enhancer activity cause transfected cells to express at least 25% of the CAT activity expressed by cells transfected with the CAT expression vector containing SEQ ID NO:2 as the enhancer sequence. This procedure is described in detail below.

25 One embodiment of the invention provides DNA, for example isolated DNA, which includes the DF3 enhancer, but does not encode DF3. "Isolated DNA" containing the DF3 enhancer refers to a segment of DNA that includes the DF3 enhancer, but which is free of the genes that, in the

2153068

- 4 -

naturally-occurring genome of the organism from which the segment is derived, flank the DF3 gene. The isolated DNA, therefore, is not immediately contiguous with both of the coding sequences with which it is immediately
5 contiguous (i.e., one at the 5' end and one at the 3' end) in the naturally-occurring genome of the organism from which the DNA of the invention is derived. The term includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously
10 replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other DNA sequences. Another aspect of the
15 invention involves DNA containing DF3 enhancer and a DNA sequence (e.g., an antisense oligomer) which is antisense to a given naturally occurring mRNA encoding a naturally occurring polypeptide, which polypeptide is not DF3. An antisense oligomer is a short (generally at least 14 bp,
20 and up to 100 or more bp) nucleotide sequence formulated to be complementary to a portion of a specific mRNA sequence. It is preferably located downstream from the enhancer of the invention and a functional promoter sequence, such as that of the HSV thymidine kinase gene;
25 a poly A tail is typically located at the end of the antisense sequence to signal the end of the sequence. Standard methods relating to antisense technology have been described (Melani et al., Cancer Res. 51:2897-2901, 1991.) Following transcription of the antisense

- 5 -

sequence into RNA, the antisense RNA binds to its target mRNA molecules within a cell, thereby inhibiting translation of the mRNA and down-regulating expression of the protein encoded by the mRNA. If, for example, the gene product of the target sequence stimulates tumor growth, down-regulation of the gene after antisense binding will result in suppression of tumor growth. Intended antisense oligodeoxynucleotides with antiproliferative activity, suitable for treatment of carcinomatous cells, include sequences antisense to N-myc in neuroectodermal cells (Whitesell et al., Mol. Cell. Biol. 11:1360-1370, 1991), c-myc for treatment of colon adenocarcinoma (Melani et al., Cancer Res. 51:2897-2901, 1991), type 1 regulatory subunit of the cAMP receptor protein kinase in breast, colon, and gastric carcinoma cells (Szczylik et al., Science 253:562-568, 1991), and K-ras proto-oncogene in small cell lung cancer lines (Vleminck et al., Cell 66:107-119, 1991).

Also provided is isolated DNA which contains the DF3 enhancer and a sequence encoding a heterologous polypeptide. A heterologous polypeptide is herein defined as any polypeptide other than DF3. The isolated DNA may include a nucleotide sequence substantially identical to that of SEQ ID NO:1, as shown in Figure 6. In other embodiments, the isolated DNA contains either the first 11 base pairs or the last 21 base pairs of SEQ ID NO:1, or both. In another embodiment of the invention, the isolated DNA includes a nucleotide sequence substantially identical to that of SEQ ID NO:2,

- 6 -

as shown in Figure 7. The invention includes variations on the enhancer sequences shown which are at least 80% identical, and preferably at least 90% identical, to the naturally-occurring sequences given in the figures, and
5 which function as enhancers of expression in carcinoma cells.

The isolated DNA of the invention may also include a radiation-inducible element. Preferably, the radiation-inducible element comprises a radiation-
10 responsive enhancer-promoter, such as a CArG domain of an *Egr-1* promoter, a TNF- α promoter, or a c-Jun promoter.

15

The heterologous polypeptide encoded by the DNA of the invention may be a cytotoxic polypeptide. Intended polypeptides include, but are not limited to, an enzymatically active subunit of a toxin such as
20 *Pseudomonas* exotoxin A, diphtheria toxin, Shiga toxin, Shiga-like toxin, *E. coli* LT, C3 toxin, pertussis toxin, tetanus toxin, cholera toxin, or botulism toxin, or another cytotoxic polypeptide such as gelonin, ricin, or tumor necrosis factor. Other possible heterologous
25 polypeptides include but are not limited to cAMP receptor polypeptide kinase, platelet factor 4, monocyte chemoattractants, herpes virus thymidine kinase, cytidine deaminase, Wtp53, retinoblastoma protein, E-cadherin,

- 7 -

fibronectin receptor, monocyte chemoattractant protein-I, interleukin-2, and interleukin-4.

The DNA or isolated DNA of the invention may be introduced into target cells by standard vectors
5 and/or gene delivery systems. Suitable gene delivery systems may include liposomes, receptor-mediated delivery systems, naked DNA, and viral vectors such as herpes viruses, retroviruses, and adenoviruses, among others. Standard methods for transfecting cells with isolated DNA
10 are well known to those skilled in the art of molecular biology.

The invention also includes cells transfected with the DNA of the invention. Preferably, the cells are epithelial cells (e.g., carcinoma cells), and they
15 express a heterologous polypeptide encoded by the DNA of the invention.

A therapeutic composition is provided which includes a pharmaceutically acceptable carrier and a therapeutically effective amount of a nucleic acid,
20 wherein the nucleic acid includes the DF3 enhancer operatively linked to a sequence encoding a heterologous polypeptide, to generate high-level expression of the polypeptide in epithelial cells transfected with the nucleic acid. By "operatively linked" it is meant that
25 the enhancer is located sufficiently close to the coding sequence that it functions to enhance expression in an epithelial cell. For example, the enhancer may be located immediately upstream of the coding sequence start site, or up to approximately 500 bp upstream of the start

2153068

- 8 -

site. It may alternatively be located downstream from the 3' end of the coding sequence, or within an intron between two exons of the coding sequence. The enhancer sequence may be inverse to the orientation observed in the naturally-occurring DF3 gene. Two or more copies of the DF3 enhancer may be arranged in tandem to increase expression of the heterologous protein to even higher levels. When the DF3 enhancer is arranged in tandem with a different tissue-specific enhancer, expression in multiple tissue types can be simultaneously enhanced. Likewise, two or more antisense or coding sequences can be arranged in tandem in the DF3-enhancer-containing DNA of the invention; expression of both of these sequences would be increased in epithelial cells, and especially in carcinoma cells. The therapeutic composition may also include a gene delivery system as described above. Pharmaceutically acceptable carriers are biologically compatible vehicles which are suitable for administration to an animal: e.g., physiological saline. A therapeutically effective amount is an amount of the DNA of the invention which is capable of producing a medically desirable result in a treated animal.

The invention provides a method for treating an animal with a carcinoma, by identifying the carcinoma-bearing animal and treating the animal with the therapeutic composition of the invention. This method may be used to treat any type of carcinoma, including but not limited to adenocarcinoma, adrenal carcinoma, basal cell carcinoma, brain carcinoma, ovarian carcinoma,

- 9 -

breast carcinoma, colon carcinoma, pancreatic carcinoma, gastric carcinoma, hepatic carcinoma, biliary system carcinoma, skin cell carcinoma, reproductive tract carcinoma, urinary organ carcinoma, small cell carcinoma, squamous-cell carcinoma, undifferentiated carcinoma, and pulmonary carcinoma. In this list, where a neoplasm is designated by organ association, as in "ovarian carcinoma" or "pulmonary carcinoma", any carcinoma located in or immediately adjacent to the organ is included, without regard to whether the carcinoma is primary or is a metastasis from another location.

In addition, the invention provides a method of treating an animal with a metabolic disorder, by administering the therapeutic composition of the invention, where the heterologous polypeptide encoded by the DNA alleviates symptoms of the metabolic disorder. This method would be useful for treatment of various metabolic diseases characterized by the absence or reduced amount of a gene product (such as phenylalanine hydroxylase resulting in classic phenylketonuria, cystic fibrosis transmembrane regulator in cystic fibrosis, or Factor VIII or IX in hemophilia), or by structurally altered genes which are functionally inactive, as with α_1 antitrypsin in emphysema. The heterologous polypeptide encoded by the DNA in the therapeutic composition would correspond to the missing or malfunctioning gene product, e.g. phenylalanine hydroxylase, the CF gene product, Factor VIII, or α_1 antitrypsin.

2153068

- 10 -

Animals intended to be treated with the methods of the invention include any mammals to which the compounds of the invention may be administered, and in which the enhancer of the invention is functional. Animals
5 specifically intended for treatment with the compounds and methods of the invention include humans, nonhuman primates, sheep, horses, cattle, pigs, goats, dogs, cats, rabbits, guinea pigs, hamsters, gerbils, rats and mice, as well as organs, tumors and cells derived or
10 originating from these hosts.

The invention also includes a method of producing a polypeptide *in vitro* by culturing a cell of epithelial origin which has been transfected with the DNA of the invention, under conditions which facilitate the
15 expression of the heterologous polypeptides encoded by the transgene. The polypeptides can then be isolated and purified by standard means.

Selective killing of cells and tumors is also encompassed by the invention. In this case, cytotoxic
20 polypeptides expressed by the transfected cells act to kill the cells, or cells in the immediate vicinity of the transfected cells. In another embodiment, the transgene also encompasses, besides the DF3 enhancer and a sequence encoding the cytotoxic polypeptide, a radiation-inducible
25 element. In this case, targeted radiation directed at a tumor, either *in vitro* or *in situ* in an animal, induces expression of a cytotoxic polypeptide only in those transfected cells which are of epithelial origin and which are irradiated. The heterologous polypeptide may

- 11 -

also be one that, when secreted by the transfected cells, is capable of recruiting the organism's natural immunological defenses to attack cells in the vicinity of the transfected cells.

5 The invention further provides a vaccine, and a method of vaccinating an animal, wherein the heterologous polypeptide associated with the DF3 enhancer includes an antigenic determinant of an infectious organism. Appropriate organisms might include bacteria, viruses,
10 protozoa, or helminths. For example, antigenic determinants of those pathogens which cause acquired immune deficiency syndrome (AIDS), polio, typhoid, cholera, and various enteric diarrheal diseases could be expressed and secreted by transfected epithelial cells
15 lining the gastrointestinal tract, and thereby confer immunity to infection by both local and systemic immunological mechanisms. Useful antigens include the B subunit of cholera toxin (Mekalanos et al., Nature 306:551-557, 1983); the B subunit of Shiga toxin/Shiga-
20 like toxin I (Calderwood et al., Proc. Natl. Acad. Sci. USA 84:4364-4368, 1987) or an antigenic peptide thereof (Harari et al., Infect. Immun. 56:1618-1624, 1988; Harari et al., Mol. Immunol. 27:613-621, 1990); an antigenic, enzymatically inactive mutant of diphtheria toxin (e.g.,
25 a deletion mutant lacking the A subunit portion of the toxin, or having an inactivating mutation in the A subunit); an antigenic, enzymatically inactive mutant of pertussis toxin, tetanus toxin, or *E. coli* LT; or a viral capsid polypeptide. Immunity to respiratory infections

2153068

- 12 -

would result from transfection of lung epithelial cells with the appropriate DNA of the invention. Similar immunization would be useful in vaccinating animals against various diseases of veterinary importance, including many parasitic diseases such as toxocariasis, filariasis, coccidiosis, strongyloidiasis, and cestodiasis. The specialized ability of epithelial cells to produce and secrete proteins makes them particularly suitable targets for DNA-based vaccines.

10 In a further embodiment of the invention, epithelial cells within an animal are transfected with DNA which includes the DF3 enhancer and a sequence encoding a polypeptide which confers resistance to the effects of a chemotherapeutic drug. In a preferred
15 example, the polypeptide encodes P-glycoprotein, the product of the multidrug resistance (MDR-1) gene. Cells which express this glycoprotein have a highly enhanced membrane transport pump, which quickly clears the cells of many common chemotherapeutic drugs, including vinca
20 alkaloids, anthracyclines, epipodophyllotoxins, L-asparaginase, colchicine, and other antineoplastic antibiotics. Another polypeptide which might be beneficially expressed by transfected epithelial cells is dihydrofolate reductase, the expression of which would
25 protect transfected cells from the toxic effects of methotrexate. Such expression in epithelial cells of a cancer patient would protect the transgenic cells from the effects of chemotherapeutics administered to treat non-carcinomatous neoplasms in the patient, without

- 13 -

affecting the efficacy of the chemotherapeutics against the non-carcinomatous neoplasm itself. The patient would then be spared the often life-threatening side effects of chemotherapy, such as gastrointestinal injury, which
5 result from epithelial cell damage. In addition, protection of the epithelial cells would allow higher doses of chemotherapeutic drugs to be administered, with potentially better clinical outcomes. In another embodiment of this method, cells of the gastrointestinal
10 tract could be protected by transfecting these cells with an orally-administered vector; nongastrointestinal malignancies, including carcinomatous and noncarcinomatous neoplasms, could then be treated with systemic chemotherapeutics with minimal effect on the
15 gastrointestinal epithelial cells.

Another aspect of the invention includes a transgenic animal, the genome of which contains a transgene including DF3 enhancer operatively linked to a sequence encoding a heterologous polypeptide. Detailed
20 methods for producing these animals are presented in U.S. Patent 4,736,866.

The intended transgenic animals may be of any nonhuman mammalian or avian species, but preferably include nonhuman primates, sheep,
25 horses, cattle, pigs, goats, dogs, cats, rabbits, chickens, and rodents such as guinea pigs, hamsters, gerbils, rats, and mice.

The compounds and compositions of the invention may be administered by any medically acceptable method.

2153068

- 14 -

Suitable methods include injections, by parenteral routes such as intravenous, subcutaneous, intramuscular, intratumor, intraperitoneal, intraventricular, intraepidural, or others, as well as oral, nasal, 5 transdermal, transmucosal, ophthalmic, rectal, or topical routes. The compounds may also be applied directly to exposed tissue surfaces, such as during a surgical procedure. In addition, the compounds of the invention are suitable for inhalant administration, for example as 10 a nebulized or aerosolized preparation.

As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of 15 administration, general health, and other drugs being administered concurrently. Dosages for the compounds of the invention will vary, but a preferred dosage for oral or inhaled administration to a patient is from 10^5 to 10^{20} copies of a DNA molecule of the invention, as specified 20 above. A patient receiving intravenous vector preparations may be infused with from approximately 10^6 to 10^{22} copies of the vector.

Other features and advantages of the invention will be apparent from the following description and from 25 the claims.

Brief Description of the Drawings

Figure 1A (SEQ ID NO:5) is a representation of the nucleotide sequence of the 5'-flanking region of the DF3

- 15 -

gene, plus the first 70 nucleotides of coding sequence. The transcription start site is indicated by the arrow. Potential binding sites with complete homology to the indicated cis-elements are highlighted by boxes.

5 Figure 1B is a transient expression analysis of DF3 promoter deletion constructs: MCF-7 cells were transfected with deleted promoter fragments linked to CAT. Relative CAT activities are expressed as values compared to that obtained with p-686CAT (assigned a value
10 of 100). The results represent the mean $\pm$ SD of the indicated number (n) of experiments.

 Figure 2A is a transient expression analysis of p-686CAT internal deletion vectors: p-686CAT was digested with BstXI and SmaI to create a construct with deletion
15 of the region from positions -603 to -410. Smaller fragments of f(-603/-410) were religated into the deleted region. Relative CAT activities are expressed as values compared to that obtained with p-686CAT. The results represent the mean $\pm$ SD of the indicated number (n) of
20 independent experiments.

 Figure 2B is a transient expression analysis of heterologous promoter constructs: Fragments of the DF3 promoter were inserted upstream to the TK promoter in pBLCAT2. MCF-7 cells were transfected with the indicated
25 constructs. The results (mean $\pm$ SD) are expressed as reactive CAT activity compared to that obtained with TK-CAT (assigned a value of 100).

 Figures 3A and B are gel retardation analyses of nucleoprotein complexes found with f(-507/-483):

2153068

- 16 -

(A) f(-507/-483) (CCGGGAAGTGGTGGGGGGAGGGAGC) (SEQ ID NO:6) was end-labeled and incubated with 10 μ g MCF-7 nuclear proteins. Unlabeled f(-507/-483) and f(-611/-579) were added at a 50- or 250-fold molar excess compared to the labeled probe. The unlabeled oligonucleotide corresponding to the consensus sequence for SP1 was added at a 50-fold molar excess.

(B) f(-507/-483) and a mutated fragment at positions -496 and -495 (CCGGGAAGTGGCAGGGGGAGGGAGC) (SEQ ID NO:7) were end-labeled (both 1×10^5 CPM, 5×10^4 CPM/ng) and incubated with MCF-7 nuclear proteins.

Figure 4 is a DNase I analysis of protein binding to f(-618/-410). f(-618/-410) was end-labeled (1×10^4 CPM/0.1 ng) and incubated with the indicated amounts of MCF-7 nuclear proteins. The samples were subjected to DNase I digestion and analyzed in 12% polyacrylamide/urea gels. C represents analysis of cytosines as determined by Maxam-Gilbert sequencing. The hatched boxes reflect regions protected from DNase I digestion.

Figure 5 is an autoradiogram of a gel illustrating f(-507/-483) interacting with a 45 kD nuclear protein in MCF-7 cells. Nuclear proteins (200 μ g) from MCF-7 and HL-60 cells were separated by polyacrylamide gel electrophoresis and transferred to a nitrocellulose sheet. Lanes were incubated with ^{32} P-f(-507/-483) in the absence or presence of a 100-fold molar excess of unlabeled fragment.

- 17 -

Figure 6 is a representation of the nucleotide sequence of a functional region of the DF3 enhancer (SEQ ID NO: 1), which represents nucleotides -598 to -485 of the 5'-flanking region of the DF3 gene shown in Figure 1A (SEQ ID NO: 2).

Figure 7 (SEQ ID NO:2) is a representation of the nucleotide sequence of the DF3 5'-flanking sequence, as shown in Figure 1A (SEQ ID NO:5), except without any of the DF3 coding sequence shown in Figure 1A.

10

Detailed Description

Cell culture. Human MCF-7 breast carcinoma cells (Michigan Cancer Foundation, Detroit, MI; American Type Culture Collection) were grown as a monolayer in Dulbecco's modified Eagle's medium (DMEM) with 10% heat-inactivated fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine and 0.25 IU/ml insulin.

Plasmid construction. A pΔ vector was generated by excising the SV40 promoter and enhancer regions from pSVT7 (Bird et al., J. Cell. Biol. 105:2905-2914, 1987). Chloramphenicol acetyltransferase (CAT) expression vectors, pSVT7CAT and pΔCAT, were produced by inserting the CAT gene in the multicloning HindIII site of pSVT7 and pΔ, respectively. A p-1656CAT vector was constructed by inserting the XmnI fragment (positions -1656 to +31) of the DF3 gene into pΔCAT at the PstI site by blunt-ended DNA ligation. The p-725CAT vector was prepared by inserting the blunt-ended SstI/XmnI fragment (positions -

2153068

- 18 -

725 to +31) into pΔCAT. A series of deletion vectors was generated from p-725CAT after treatment with SstI or XbaI and subsequent digestion with exonuclease III and S1 nuclease. Sequencing of the constructs was performed by dideoxy termination (Sanger et al., Proc. Natl. Acad. Sci. USA 74:5463-5467, 1977).

Reporter assays. All vectors used in the reporter assays were purified twice by cesium chloride gradient centrifugation and phenol-chloroform extraction. Twenty μg of each plasmid were transfected into 3×10^5 MCF-7 cells by the Ca_2PO_4 procedure (Davis et al., Basic Methods in Molecular Biology (Elsevier, NY) pp. 285-289, 1986). The cells were incubated in complete medium for 48 hours after transfection, harvested and lysed in 0.25 M Tris-HCl (pH 8.0) by three cycles of freeze-thawing. CAT activity was assayed in 125 μl reactions containing 10 to 50 μl of cell extract, 125 nCi [^{14}C]chloramphenicol (DuPont Co., Boston, MA; 57 mCi/mmol), 250 mM Tris-HCl, pH 8.0, and 25 μg n-butyryl coenzyme A (Sigma) for 1 hour at 37°C. The reaction was terminated by adding 300 μl xylene. The non-butyrylated chloramphenicol was removed by washing twice with 100 μl of 0.25 M Tris-HCl (pH 8.0). The xylene layer containing the butyrylated chloramphenicol was assayed by scintillation counting (Seed et al., Gene 67:271-277, 1988).

Electrophoretic mobility shift assays (EMSAs). Nuclear proteins were prepared according to previously described methods (Dignam et al., Nucl. Acids. Res. 11:1475-1489, 1983). Synthetic oligonucleotides were

- 19 -

end-labeled with the appropriate [α - ^{32} P]dNTPs using DNA polymerase I (Klenow fragment) and purified by Nuc Trap columns (Stratagene, LaJolla, CA). Binding assays were performed as described (Henninghausen et al., Guide to Molecular Cloning Techniques, (Academic Press, NY) pp. 721-735, 1987). Ten μ g of nuclear proteins were incubated with 10 μ g poly(dI-dC) in 25 μ l of 10 mM Tris-HCl buffer (pH 7.5) containing 50 or 150 mM KCl, 5 mM MgCl₂, 1 mM DTT, 1 mM EDTA, 12.5% glycerol and 0.1% Triton X-100 for 30 min at room temperature. After adding the labeled probe (1×10^5 CPM, 1 ng) and incubating for an additional 30 min, the samples were separated in a low ionic strength 4.5% polyacrylamide gel containing 1 mM EDTA, 3.3 mM sodium acetate and 6.7 mM Tris-HCl (pH 7.5) or in a high ionic strength gel containing 50 mM Tris-HCl (pH 8.5), 380 mM glycine and 2 mM EDTA (Henninghausen et al., Guide to Molecular Cloning Techniques (Academic Press NY) pp. 721-735, 1987; Staudt et al., Nature 323:640-643, 1986). Unlabeled oligonucleotides as competitors, including the consensus sequences of SP1, NF-1, AP-1, AP-2 and AP-3 (Stratagene), were added at the same time as the labeled fragment.

DNase I footprint analysis. Fragment f(-618/-410) (SEQ ID NO:8) was ligated into pGEM3 at the SmaI site. The vector was digested with EcoRI and AccI, end-labeled with ^{32} P-dATP and dTTP at the EcoRI site and purified in a 5% native polyacrylamide gel. The specific activity of the labeled fragment was approximately 3×10^5 CPM/ng. The assay was performed as described (Jones et al., Cell

- 20 -

42:559-572, 1985). The reaction products were analyzed by 12% polyacrylamide/urea gel electrophoresis and subjected to autoradiography. Sequences were monitored by the Maxam-Gilbert procedure (Maxam et al., Methods in Enzymol. (Academic Press, NY) 65:499-560, 1980).

Southwestern analysis. Nuclear proteins (200 µg) were prepared as described (Dignam et al., Nucl. Acids. Res. 11:1475-1489, 1983), separated by 3-15% SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose sheet (Lammli, Nature 227:680-695, 1970; Towbin et al., Proc. Natl. Acad. Sci. USA 76:4350-4355, 1979). The sheet was incubated in 10 mM Tris-HCl (pH 7.5) containing 5% skimmed milk and then in 10 mM Tris-HCl (pH 7.9) containing ³²P-labeled oligonucleotide probe (10⁶ CPM/ml), 50 mM NaCl, 10 mM MgCl₂, 0.1 mM EDTA, 1 mM DTT and 10 µg/ml poly(dI-dC) for 60 min at room temperature. The sheet was washed with the same buffer containing 200 mM NaCl and exposed to x-ray film (Patel et al., EMBO J. 2:137-142, 1983; Miskimins et al., Proc. Natl. Acad. Sci. USA 82:6741-6744, 1985).

RESULTS

Sequence of the DF3 5'-flanking region. A genomic library from MCF-7 cells was previously used to isolate a clone containing over 2 kb of sequences upstream to the DF3 transcription start site (Abe et al., Biochem. Biophys. Res. Commun. 165:644-649, 1989).

Digestion of this clone with XmnI resulted in a fragment extending from positions -1656 to +31. The nucleotide sequence to position -1656

- 21 -

includes a potential TATA box (TATAAA) 25 bases upstream to the transcription start site (Figure 1A). The 5' flanking region also includes potential binding sites with complete homology to the consensus sequences for SP1, AP-1, AP-2, AP-3, NF-1 and the estrogen receptor half-site (Figure 1A).

Functional analysis of the putative DF3 promoter region. A series of experiments confirmed that DF3 gene expression is regulated at the transcriptional level in MCF-7 cells. A series of 5' deleted DF3 promoter-CAT constructs were transfected into these cells to identify the functional cis-element(s). Transfection of plasmid p-1656CAT resulted in CAT activities that were approximately 25-fold higher than that obtained with pΔCAT (Figure 1B). Similar levels of CAT activity were obtained with p-725CAT, p-686CAT and p-618CAT (Figure 1B). In contrast, transfection of p-549CAT was associated with a decrease in transcriptional activity to approximately 15% of that found with p-686CAT. Moreover, transfection of the more extensively deleted constructs (p-448CAT, p-324CAT, p-167CAT) yielded levels of relative activity that were similar to those obtained with constructs containing a minimal promoter region (p-19CAT) (Figure 1B). Taken together, these findings indicated that the sequence between positions -618 and -549 includes one or more elements involved in the control of DF3 gene transcription.

In order to further define the functional element(s), a series of internal deletions was prepared

2153068

- 22 -

using p-686CAT. Deletion of the region from positions - 603 to -410 decreased (>80%) transcription of p-686CAT to a level approaching that obtained with p-549CAT (Figure 2A). Similar findings were obtained with reinsertion of f(-410/-505) or f(-481/-410) (Figure 2A). These results were thus in concert with the likelihood that the functional enhancer sequences were upstream to position - 549 (Figure 1B). However, ligation of f(-505/-588) into this cassette had little if any effect, while reinsertion of f(-600/-505) or f(-505/-600) resulted in only partial (54-60%) recovery of CAT activity (Figure 2A). In contrast, f(-485/-598) conferred complete restitution of the activity obtained with p-686CAT (Figure 2A). These results indicated that sequences within f(-598/-485) were responsible for control of DF3 gene transcription.

A heterologous promoter was used to determine the enhancing activities of sequences upstream to position - 485. Single copies of fragments f(-753/-505), f(-485/-598), f(-505/-588) and f(-505/-614) were inserted upstream to the herpes simplex virus minimal thymidine kinase (TK) promoter in pBLCAT2 (Figure 2B). CAT activity of pBLCAT2 was normalized to 100. Insertion of f(-753/-505) into this vector had little if any effect, while f(-485/-598) enhanced TK promoter activity by over 10-fold (Figure 2B). These results provided further support for the presence of functional elements between positions -598 and -485. Moreover, the finding that both f(-505/-588) and f(-505/-614) decreased the activity of

- 23 -

pBLCAT2 (Figure 2B) emphasized the importance of the sequence between -505 and -485.

Interaction of nuclear proteins with the DF3 promoter. The results of the reporter assays prompted
5 further studies on the interaction of nuclear proteins with the putative regulatory regions of the DF3 promoter. EMSAs were performed with f(-507/-483). Incubation of end-labeled f(-507/-483) with nuclear proteins from MCF-7 cells resulted in a clearly detectable retarded fragment
10 (Figure 3A). In order to determine whether this complex reflected specific DNA-protein binding, unlabeled f(-507/-483) was added to the reaction. In these experiments, a 50-fold excess of unlabeled probe partially inhibited formation of the complex, while a
15 250-fold excess resulted in complete inhibition (Figure 3A). In contrast, use of unlabeled f(-611/-579) as a competitor had no detectable effect (Figure 3A). There was also no detectable inhibition of this complex when using unrelated oligonucleotides containing SP1, AP-1,
20 AP-2, AP-3, or NF-1 sequences (Figure 3A and data not shown). These findings, taken together with the absence of a detectable band when using nuclear proteins from HL-60 (DF3 antigen negative cells, data not shown), supported the formation of a specific f(-507/483)-MCF-7
25 nuclear protein complex. There was also no detectable complex formation when incubating labeled f(-515/-496) or f(-529/-510) with the MCF-7 nuclear proteins (data not shown). Finally, alterations in the sequence of f(-507/-

2153068

- 24 -

483) at positions -496/-495 resulted in nearly complete inhibition of complex formation (Figure 3B).

The interaction of nuclear proteins with the DF3 promoter was further addressed by DNaseI footprinting. 5 End-labeled f(-618/-410) was incubated with increasing amounts of MCF-7 nuclear proteins and then subjected to digestion with DNase I. The demonstration that one protected region extended from positions -485 to -505 (Figure 4) is in concert with the sequences identified by 10 reporter and gel retardation assays. Another region extending from positions -513 to -525 was also protected by MCF-7 nuclear proteins (Figure 4). Moreover, there was enhancement of sequences adjacent to the protected regions (at positions -506 to -510 and upstream to 15 position -530) (Figure 4).

Southwestern analysis was performed to identify the size of the protein(s) that interact with f(-507/-483). This fragment interacted with a species with an apparent molecular weight of 45 kd (Figure 5). This 20 interaction was inhibited by a 100-fold excess of unlabeled to labeled fragment. In contrast, there was no detectable interaction of f(-507/-483) with nuclear proteins from HL-60 cells (Figure 5). Moreover, incubation of labeled f(-611/-579) with the MCF-7 nuclear 25 proteins failed to demonstrate DNA-protein interaction (data not shown). Taken together, these results indicated that f(-507/-483) specifically interacts with a nuclear 45 kD protein.

- 25 -

Example

A patient is diagnosed with a malignant inoperable pulmonary carcinoma. Using standard methods, a genetic construct is prepared bearing the DF3 enhancer operably
5 linked to the gene for herpes simplex-thymidine kinase (HS-tk). The HS-tk gene, when introduced into tumor cells, confers sensitivity to the anti-herpes drug gancyclovir. The construct is inserted into a retroviral vector, and 10^8 copies of the vector are injected into
10 the tumor. Of all of the cells which may take up the vector, only the transfected carcinoma cells which naturally overexpress DF3 will highly overexpress the HS-tk transgene. The patient is then treated with gancyclovir, which acts primarily on those cells which
15 overexpress HS-tk, causing the tumor to regress.

Other Embodiments

The invention includes the use of the DF3 enhancer to modulate expression of any protein which is either partially or wholly encoded in a location downstream to
20 the DF3 enhancer. Also included are allelic variants, natural mutants, and induced mutants of the DF3 enhancer, which variants and mutants retain the ability to enhance expression in epithelial cells comparable to the level of enhancement produced by the sequence shown in SEQ ID
25 NO:1.

Similar enhancers derived from corresponding genes in other mammalian species are included within the scope

2153068

- 26 -

of the invention. Such enhancers may be identified by, for example, identifying the enhancer associated with a coding sequence from a particular mammalian species, which coding sequence hybridizes under stringent

5 conditions with a probe consisting of a 20-nucleotide segment of the human DF3 coding sequence, and which encodes a polypeptide that is expressed predominantly in epithelial cells of that species. Alternatively, a probe consisting of a segment of the human DF3 enhancer can be

10 used as a probe for a similar sequence in the genome or cDNA of another species. A sequence which functions as an epithelium-specific enhancer and which hybridizes with a probe containing the sequence of SEQ ID NO:1 or the sequence of SEQ ID NO:4, under the following

15 hybridization conditions, would be within the invention: prehybridization in 50% formamide, 5X SSC, 25 mM potassium phosphate buffer (pH 7.4), 5X Denhardt's, and 50 µg/ml denatured salmon sperm DNA for 4-12 hours at 20°C; hybridization for 12-24 hours at 20°C; washing in

20 5X SSC containing 0.1% SDS, at 20°C.

- 27 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Kufe, Donald
Abe, Miyako

(ii) TITLE OF INVENTION: ENHANCER SEQUENCE FOR
MODULATING EXPRESSION IN
EPITHELIAL CELLS

(iii) NUMBER OF SEQUENCES: 8

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Fish & Richardson
(B) STREET: 225 Franklin Street
(C) CITY: Boston
(D) STATE: Massachusetts
(E) COUNTRY: U.S.A.
(F) ZIP: 02110-2804

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
(B) COMPUTER: IBM PS/2 Model 50Z or 55SX
(C) OPERATING SYSTEM: MS-DOS (Version 5.0)
(D) SOFTWARE: WordPerfect (Version 5.1)

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 07/999,742
(B) FILING DATE: December 31, 1992

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Fraser, Janis K.
(B) REGISTRATION NUMBER: 34,819
(C) REFERENCE/DOCKET NUMBER: 00530/065WO1

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617) 542-5070
(B) TELEFAX: (617) 542-8906
(C) TELEX: 200154

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 114
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

2153068

- 28 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CTGGAAAGTC CGGCTGGGGC GGGGACTGTG GGTTTCAGGG TAGAACTGCG TGTGGAACGG 60
GACAGGGAGC GGTTAGAAGG GTGGGGCTAT TCCGGGAAGT GGTGGGGGGA GGGA 114

(3) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1656
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GCTTCCGTGC GCCTAGAGCG CAGCCTGCGA CTGCGGGACC CAACAACCAC GTGCTGCCGC 60
GGCCTGGGAT AGCTTCCTCC CCTCTGGCAC TGCTGCCGCA CACACCTCTT GGCTGTCGCG 120
CATTACGCAC CTCACGTGTG CTTTGGCCCC CGCCTACGTG CCTACCTGTC CCCAATACCA 180
CTCTGCTCCC CAAAGGATAG TTCTGTGTCC GTAAATCCCA TTCTGTCACC CCACCTACTC 240
TCTGCCCCCC CCTTTTTTGT TTTGAGACGG AGTCTTGCTC TGTCGCCCAG GCTGGAGTGC 300
AATGGCGCGA TCTCGGCTCA CTGCAACCTC CGCCTCCCGG GTTCAAGCGA TTCTCCTGCC 360
TCAGCCTCCT GAGTAGCTGG GGTTACAGCG CCCGCCACCA CGCTCGGCTA ATTTTGTAG 420
TTTTTAGTAG AGACGAGGTT TCACCATCTT GGCCAGGCTG GTCTTGAACC CCTGACCTTG 480
TGATCCACTC GCCTCGGCCT TCCAAAGTGT TGGGATTACG GCGGTGACGA CCGTGCCACG 540
CCCGATCTGC CTCTTAAGTA CATAACGGCC CACACAGAAC GTGTCCAACCT CCCCCGCCCA 600
CGTTCCAACG TCCTCTCCCA CATACTCGG TGCCCCCTTC ACATACCTCA GGACCCACCC 660
CGCTTAGCTC CATTTCTCTC AGACGCCACC ACCACGCGTC CCGGAGTGCC CCCTCCTAAA 720
GCTCCCAGCC GTCCACCATG CTGTGCGTTC CTCCCTCCCT GGCCACGGCA GTGACCCTTC 780
TCTCCCGGGC CCTGCTTCCC TCTCGCGGGC TCTCGCTGCC TCACTTAAGC AGCGCTGCCC 840
TACTCCTCT CCGCCCGGTC CGAGCGGCCC CTCAGCTTGC GCGGCCCAGC CCCGCAAGGC 900
TCCCGGTGAC CACTAGAGGG CGGGAGGAGC TCCTGGCCAG TGGTGGAGAG TGGCAAGGAA 960
GGACCCTAGG GTTCATCGGA GCCCAGGTTT ACTCCCTTAA GTGGAAATTT CTCCCCCAC 1020
TCCCTCCTTG GCTTCTCCA AGGAGGGAAC CCAGGCTGCT GGAAAGTCCG GCTGGGGCGG 1080
GGACTGTGGG TTTCAGGGTA GAACTGCGTG TGGAACGGGA CAGGGAGCGG TTAGAAGGGT 1140
GGGGCTATTC CGGGAAGTGG TGGGGGGAGG GAGCCCAAAA CTAGCACCTA GTCCACTCAT 1200
TATCCAGCCC TCTTATTTCT CGGCCCCGCT CTGCTTCAGT GGACCCGGGG AGGGCGGGGA 1260
AGTGGAGTGG GAGACCTAGG GGTGGGCTTC CCGACCTTGC TGTACAGGAC CTCGACCTAG 1320

- 29 -

CTGGCTTTCT TCCCCATCCC CACGTTAGTT GTTGCCCTGA GGCTAAACT AGAGCCCAGG 1380
 GGCCCCAAGT TCCAGACTGC CCCTCCCCC TCCCCCGGAG CCAGGGAGTG GTTGGTGAAA 1440
 GGGGGAGGCC AGCTGGAGAA CAAACGGGTA GTCAGGGGGT TGAGCGATTA GAGCCCTTGT 1500
 ACCCTACCCA GGAATGGTTG GGGAGGAGGA GGAAGAGGTA GGAGGTAGGG GAGGGGGCGG 1560
 GGTTTTGTCA CCTGTCACCT GCTCCGGCTG TGCCTAGGGC GGGCGGGCGG GGAGTGGGGG 1620
 GACCGGTATA AAGCGGTAGG CGCCTGTGCC CGCTCC 1656

(4) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CTGGAAAGTC C 11

(5) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GGGAAGTGGT GGGGGGAGGG A 21

(6) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1725
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GCTTCCGTGC GCCTAGAGCG CAGCCTGCGA CTGCGGGACC CAACAACCAC GTGCTGCCGC 60
 GGCTGGGAT AGCTTCCTCC CCTCTGGCAC TGCTGCCGCA CACACCTCTT GGCTGTCGCG 120
 CATTACGCAC CTCACGTGTG CTTTGGCCCC CGCCTACGTG CCTACCTGTC CCCAATACCA 180
 CTCTGCTCCC CAAAGGATAG TTCTGTGTCC GTAAATCCCA TTCTGTCACC CCACCTACTC 240
 TCTGCCCCC CCTTTTTTGT TTTGAGACGG AGTCTTGCTC TGTCGCCCAG GCTGGAGTGC 300

- 30 -

AATGGCGCGA TCTCGGCTCA CTGCAACCTC CGCCTCCCGG GTTCAAGCGA TTCTCCTGCC	360
TCAGCCTCCT GAGTAGCTGG GGTACAGCG CCCGCCACCA CGCTCGGCTA ATTTTGTAG	420
TTTTTAGTAG AGACGAGGTT TCACCATCTT GGCCAGGCTG GTCTTGAACC CCTGACCTTG	480
TGATCCACTC GCCTCGGCCT TCCAAAGTGT TGGGATTACG GGC GTGACGA CCGTGCCACG	540
CCCGATCTGC CTCTTAAGTA CATAACGGCC CACACAGAAC GTGTCCAACCT CCCCCGCCCA	600
CGTTCCAACG TCCTCTCCCA CATACTCGG TGCCCCCTTC ACATACCTCA GGACCCACCC	660
CGCTTAGCTC CATTCCTCC AGACGCCACC ACCACGCGTC CCGGAGTGCC CCCTCCTAAA	720
GCTCCCAGCC GTCCACCATG CTGTGCGTTC CTCCCTCCCT GGCCACGGCA GTGACCCTTC	780
TCTCCCGGGC CCTGCTTCCC TCTCGCGGGC TCTCGCTGCC TACTTAAGC AGCGCTGCCC	840
TTACTCCTCT CCGCCCGGTC CGAGCGGCCC CTCAGCTTGC GCGGCCCAGC CCGCAAGGC	900
TCCCGGTGAC CACTAGAGGG CGGGAGGAGC TCCTGGCCAG TGGTGGAGAG TGGCAAGGAA	960
GGACCCTAGG GTTCATCGGA GCCCAGGTTT ACTCCCTTAA GTGGAAATTT CTTCCCCCAC	1020
TCCCTCCTTG GCTTTCTCCA AGGAGGGAAC CCAGGCTGCT GGAAAGTCCG GCTGGGGCGG	1080
GGACTGTGGG TTTCAGGGTA GAACTGCGTG TGGAACGGGA CAGGGAGCGG TTAGAAGGGT	1140
GGGGCTATTC CGGGAAGTGG TGGGGGGAGG GAGCCCCAAA CTAGCACCTA GTCCACTCAT	1200
TATCCAGCCC TCTTATTCTT CGGCCCCGCT CTGCTTCAGT GGACCCGGGG AGGGCGGGGA	1260
AGTGGAGTGG GAGACCTAGG GGTGGGCTTC CCGACCTTGC TGTACAGGAC CTCGACCTAG	1320
CTGGCTTTCT TCCCCATCCC CACGTTAGTT GTTGCCCTGA GGCTAAAACT AGAGCCCAGG	1380
GGCCCCAAGT TCCAGACTGC CCCTCCCCC TCCCCCGGAG CCAGGGAGTG GTTGGTGAAA	1440
GGGGGAGGCC AGCTGGAGAA CAAACGGGTA GTCAGGGGGT TGAGCGATTA GAGCCCTTGT	1500
ACCCTACCCA GGAATGGTTG GGGAGGAGGA GGAAGAGGTA GGAGGTAGGG GAGGGGGCGG	1560
GGTTTTGTCA CCTGTCACCT GCTCCGGCTG TGCCTAGGGC GGGCGGGCGG GGAGTGGGGG	1620
GACCGGTATA AAGCGGTAGG CGCCTGTGCC CGCTCCACCT CTCAAGCAGC CAGCGCCTGC	1680
CTGAATCTGT TCTGCCCCCT CCCCACCCAT TTCACCACCA CCATG	1725

(7) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	double
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

CCGGGAAGTG GTGGGGGGAG GGAGC 25

- 31 -

(8) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 7:**(i) SEQUENCE CHARACTERISTICS:**

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	double
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CCGGGAAGTG GCAGGGGGAG GGAGC 25

(9) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 8:**(i) SEQUENCE CHARACTERISTICS:**

(A) LENGTH:	209
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	double
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

CAAGGAGGGA ACCCAGGCTG CTGGAAAGTC CGGCTGGGGC GGGGACTGTG GGTTTCAGGG	60
TAGAACTGCC TGTGGAACGG GACAGGGAGC GGTTAGAAGG GTGGGGCTAT TCCGGGAAGT	120
GGTGGGGGGA GGGAGCCCAA AACTAGCACC TAGTCCACTC ATTATCCAGC CCTCTTATTT	180
CTCGGCCCCG CTCTGCTTCA GTGGACCCG	209

- 32 -

Claims

1. DNA comprising: (i) the nucleotide sequence of SEQ ID NO:8, or a fragment thereof; or (ii) a sequence which is at least 80% identical to SEQ ID NO:8, wherein the DNA does not encode DF3 and functions as an epithelium specific enhancer.
5
2. The DNA of claim 1, wherein the fragment comprises SEQ ID NO:1 or a polynucleotide at least 80% identical to SEQ ID NO:1.
- 10 3. The DNA of claim 1, wherein the fragment comprises nucleotides -600 to -505 as shown in Fig. 1A.
4. The DNA of claim 1, wherein the fragment comprises the nucleotide sequence of SEQ ID NO:3.
5. The DNA of any one of claims 1 to 4, wherein the
15 fragment comprises the nucleotide sequence of SEQ ID NO:3 and the nucleotide sequence of SEQ ID NO:4.
6. Isolated DNA comprising a polynucleotide as defined in any one of claims 1 to 5, further comprising a nucleotide sequence selected from (a) a sequence encoding a
20 heterologous polypeptide; and (b) a sequence which is capable of being transcribed into an RNA antisense to a naturally occurring mRNA, which mRNA is not DF3 mRNA.

- 33 -

7. The DNA of claim 6, wherein said RNA antisense to a naturally occurring mRNA down-regulates expression of a target protein encoded by the mRNA molecules within a cell.

8. The DNA of claim 6, wherein said heterologous polypeptide is selected from: an enzymatically active subunit of Pseudomonas exotoxin A, diphtheria toxin, Shiga toxin, Shiga-like toxin, E-coli LT, C3 toxin, pertussis toxin, tetanus toxin, cholera toxin, or botulism toxin; gelonin; ricin; tumor necrosis factor; polypeptide kinase; platelet factor 4; monocyte chemoattractants; herpes virus thymidine kinase; cytidine deaminase; WTP53; retinoblastoma protein; E-cadherin; fibronectin receptor; monocyte chemoattractant protein-I; interleukin-2; and interleukin-4.

9. The DNA of claim 7, wherein said RNA antisense to a naturally occurring mRNA is a sequence selected from a sequence antisense to N-myc in neuroectodermal cells, c-myc in colon adenocarcinoma cells, type 1 regulatory subunit of the cAMP receptor protein kinase in breast, colon, and gastric carcinoma cells and K-ras proto-oncogene in small cell lung cancer cells.

10. The DNA of any one of claims 1 to 9, wherein the DNA further comprises a radiation-inducible element.

11. The DNA of claim 6, wherein the heterologous polypeptide is selected from: a cytotoxic polypeptide; a gene product, the absence or inadequate level of which is responsible for a metabolic disorder; a polypeptide containing an antigenic determinant of an infectious

- 34 -

organism; and a polypeptide which confers resistance to the effects of a chemotherapeutic drug.

12. The DNA of claim 11, wherein the heterologous polypeptide is a cytotoxic polypeptide.

5 13. A vector comprising the polynucleotide or DNA of any one of claims 1 to 12.

14. A cell containing the polynucleotide or DNA of any one of claims 6 to 12.

10 15. The cell of claim 14, wherein the cell is an epithelial cell.

16. The cell of claim 14 or 15, wherein the cell is a carcinoma cell.

15 17. A therapeutic composition comprising a pharmaceutically acceptable carrier and a therapeutically-effective amount of a nucleic acid, wherein the nucleic acid comprises DNA or a polynucleotide as claimed in any one of claims 6 to 12.

20 18. A therapeutic composition as claimed in claim 17, wherein said nucleic acid comprises or is operably linked to DNA encoding a heterologous polypeptide wherein said polypeptide is selected from the group consisting of phenylalanine hydroxylase, alpha antitrypsin, cystic fibrosis transmembrane regulator, Factor VIII and Factor IX.

- 35 -

19. Use of a DNA or polynucleotide as claimed in any one of claims 1 to 12, in the preparation of a therapeutic composition for use in the treatment of carcinoma or metabolic disorders, for conferring resistance to the effects of a chemotherapeutic drug or for use as a vaccine against an infectious organism.

20. Use as claimed in claim 19, wherein said composition is for use in the treatment of a carcinoma selected from the group consisting of adenocarcinoma, adrenal carcinoma, basal cell carcinoma, brain carcinoma, ovarian carcinoma, breast carcinoma, colon carcinoma, pancreatic carcinoma, gastric carcinoma, hepatic carcinoma, biliary system carcinoma, skin cell carcinoma, reproductive tract carcinoma, urinary organ carcinoma, small cell carcinoma, squamous cell carcinoma, undifferentiated carcinoma, and pulmonary carcinoma.

21. Use as claimed in claim 19 or 20, wherein said DNA or polynucleotide is capable of being transcribed into a transcript antisense to a naturally occurring mRNA, wherein said transcript has anti-proliferative activity against carcinoma cells.

22. Use as claimed in any one of claims 19 to 21, wherein said therapeutic composition further comprises a gene delivery system for introducing said DNA or polynucleotide into a target cell.

23. A method of preparing a polypeptide in vitro comprising culturing a cell of epithelial origin which has been transfected with DNA as claimed in any one of claims 6, 8 or

- 36 -

10 to 12, under conditions which facilitate the expression of the heterologous polypeptide, and recovering the polypeptide thus produced.

24. The DNA or polynucleotide of any one of claims 6 to 12
5 for use in the treatment of carcinoma or metabolic disorders, for conferring resistance to the effects of a chemotherapeutic drug or for use as a vaccine against an infectious organism.

25. The DNA or polynucleotide of claim 24, wherein the
10 carcinoma is selected from the group consisting of adenocarcinoma, adrenal carcinoma, basal cell carcinoma, brain carcinoma, ovarian carcinoma, breast carcinoma, colon carcinoma, pancreatic carcinoma, gastric carcinoma, hepatic carcinoma, biliary system carcinoma, skin cell carcinoma,
15 reproductive tract carcinoma, urinary organ carcinoma, small cell carcinoma, squamous cell carcinoma, undifferentiated carcinoma, and pulmonary carcinoma.

2153068

1/9

5'-
 -1656 GCTTCCGTGC GCCTAGAGCG CAGCCTGCGA CTGGGGGACC CAACAACCAC GTGCTGCCGC GGCTGGGAT AGCTTCCTCC CCTCTGGCAC TGCTGCCGCA
 -1556 CACACCTCTT GGCTGTGCGG CATTAGGCAC CTCACGTGTG CTTTGGCCCC CGCCTACGTG CCTACCTGTC CCCAATACCA CTCTGCTCCC CAAAGGATAG
 -1456 TTCTGTGTCC GTAAATCCCA TTCTGTCACTC CCACCTACTC TCTGCCCCCC CCTTTTGT TTTGAGACGG AGTCTTGCTC TGTCGCCCAG GCTGGAGTGC
 -1356 AATGGCGCGA TCTCGGCTCA CTGCAACCTC CGCCTCCCGG GTTCAAGCGA TTCTCCTGCC TCAGCCTCCT GAGTAGCTGG GGTACAGCG CCCGCCACCA
 -1256 CGCTCGGCTA ATTTTGTAG TTTTGTAG AGACGAGGT TCACCATCTT GGCGGGCTG GTCTTGAACC CTGACCTTG TGATCCACTC GCCTCGGCCT SP1
 -1156 TCCAAAGTGT TGGGATTACG GCGGTGACGA CCGTGCCACG CCCGATCTGC CTCTTAAGTA CATAACGGCC CACACAGAAC GTGTCCAAC CCCGCCCA
 -1056 CGTTCCAACG TCCTCTCCCA AP-1 CATACTCTCG TGCCCTCTCC ACATACCTCA GGACCCACCG CGCTTAGCTC CATTCCTCC AGACGCCACC ACCACGGTC
 - 956 CCGGAGTGCC CCTCTCTAA GCTCCACGCC GTCCACCATG CTGTGGGTC CTCCCTCCCT GGCCACGGCA GTGACCTTC TCTCCCGGGC CCTGCTTCCC
 - 856 TCTCGGGGC ER TCTCGTGCC TCACTTAAGC AGCGTGCCC TTA^{AP-1}CTCTCT CEGCGGGTC CGAGCGGCC CTCAGCTGC GCGGCCCAGC CCCGCAAGGC
 - 756 TCCCGGTGAC ACTAGAGG CGGAGGAGC TCCTGGCCAG TGGTGGAGAG TGGCAAGGAA GGACCTTAGG GTTCATCGGA GCCAGGTTT ACTCCCTTAA
 - 656 GTGGAATT CTTCCTCCAC TCCCTCCTTG GCTTCTCCA AGGAGGAAC CCAGGCTGCT GGAAAGTCG AP-3 GCTGGGCGG SP1 GGACTGTGG TTTACGGTA
 - 556 GAACTGCGTG TGAACGGGA CAGGAGCGG TTAGAAGGT GGGCTATTG CGGGAAGTGG TGGGGGAGG GAGCCCAAA CTAGCACCTA GTCCACTCAT
 - 456 TATCCAGCCC TCTTATTCT CGGCCCGGCT CTGCTTCACT GGACCCGGG AGGCGGGGA AGTGGAGTGG GAGACCTAGG GGTGGGCTC CCGACCTTGC
 - 356 TGTACAGGAC CTCGACCTAG CTGGCTTCT TCCCATCCC CACGTAGTT GTTGCCCTGA GGCTAAACT AGAGCCACAG GCGCCCAAGT TCCAGACTGC
 - 256 CCTTCCCCC TCCCCCGGAG CCAGGAGTG GTTGTGAAA GCGGAGGCC SP1 AGCTGGAGAA CAAACGGTA GTCAGGGGT TGAGCGATTA GAGCCCTTGT
 - 156 ACCCTACCA GGAATGTTG GGGAGGAGTA GGAAGAGTA GGAGGTAGG GAGGGGCGG GGTTTGTCA CCTGTACCT GCTCCGGCTG TGCCTAGGGC SP1
 - 56 GGGCGGCGG GGAGTGGGG GACCGGTATA AAGCGGTAGG CGCCTGTGCC CGCTCCACT CTCAAGCAGC CAGCGCCTGC CTGAATCTGT TCTGCCCCCT
 + 45 CCCCACCCAT TTCACCACCA CCATG

FIG. 1A

2153068

2/9





FIG. 1B

2153068

3/9






FIG. 2B

2153068

5/9




FIG. 3A

FIG. 3B

2153068




FIG. 4

7/9




FIG. 5

2153068

8/9

CTGGAAAGTC CGGCTGGGGC GGGGACTGTG GGTTTCAGGG TAGAACTGCG TGTGGAACGG 60
GACAGGGAGC GGTTAGAAGG GTGGGGCTAT TCCGGGAAGT GGTGGGGGGA GGGA 114

FIG. 6

2153068

9/9

GCTTCCGTGC GCCTAGAGCG CAGCCTGCGA CTGCGGGACC CAACAACCAC GTGCTGCCGC 60
GGCCTGGGAT AGCTTCCTCC CCTCTGGCAC TGCTGCCGCA CACACCTCTT GGCTGTCGCG 120
CATTACGCAC CTCACGTGTG CTTTTGCCCC CGCCTACGTG CCTACCTGTC CCCAATACCA 180
CTCTGCTCCC CAAAGGATAG TTCTGTGTCC GTAAATCCCA TTCTGTCACC CCACCTACTC 240
TCTGCCCCCC CTTTTTTTGT TTTGAGACGG AGTCTTGCTC TGTCGCCCAG GCTGGAGTGC 300
AATGGCGCGA TCTCGGCTCA CTGCAACCTC CGCCTCCCGG GTTCAAGCGA TTCTCCTGCC 360
TCAGCCTCCT GAGTAGCTGG GGTACAGCG CCCGCCACCA CGCTCGGCTA ATTTTTGTAG 420
TTTTTAGTAG AGACGAGGTT TCACCATCTT GGCCAGGCTG GTCTTGAACC CCTGACCTTG 480
TGATCCACTC GCCTCGGCCT TCCAAAGTGT TGGGATTACG GGCGTGACGA CCGTGCCACG 540
CCCGATCTGC CTCTTAAGTA CATAACGGCC CACACAGAAC GTGTCCAACCT CCCCCGCCCA 600
CGTTCCAACG TCCTCTCCCA CATACTCGG TGCCCCTTCC ACATACCTCA GGACCCCACC 660
CGCTTAGCTC CATTCCTCC AGACGCCACC ACCACGCGTC CCGGAGTGCC CCCTCCTAAA 720
GCTCCCAGCC GTCCACCATG CTGTGCGTTC CTCCCTCCCT GGCCACGGCA GTGACCCTTC 780
TCTCCCGGGC CCTGCTTCCC TCTCGCGGGC TCTCGCTGCC TCACTTAAGC AGCGCTGCCC 840
TACTCCTCT CCGCCCGGTC CGAGCGGCCC CTCAGCTTGC GCGGCCCAGC CCGCAAGGC 900
TCCCGGTGAC CACTAGAGGG CGGGAGGAGC TCCTGGCCAG TGGTGGAGAG TGGCAAGGAA 960
GGACCCTAGG GTTCATCGGA GCCCAGGTTT ACTCCCTTAA GTGGAAATTT CTTCCCCCAC 1020
TCCCTCCTTG GCTTTCTCCA AGGAGGGAAC CCAGGCTGCT GGAAAGTCCG GCTGGGGCGG 1080
GGACTGTGGG TTTCAGGGTA GAACTGCGTG TGGAACGGGA CAGGGAGCGG TTAGAAGGGT 1140
GGGGCTATTC CGGGAAGTGG TGGGGGGAGG GAGCCCAAAA CTAGCACCTA GTCCACTCAT 1200
TATCCAGCCC TCTTATTTCT CGGCCCCGCT CTGCTTCAGT GGACCCGGGG AGGGCGGGGA 1260
AGTGGAGTGG GAGACCTAGG GGTGGGCTTC CCGACCTTGC TGTACAGGAC CTCGACCTAG 1320
CTGGCTTTCT TCCCCATCCC CACGTTAGTT GTTGCCCTGA GGCTAAAACT AGAGCCCAGG 1380
GGCCCCAAGT TCCAGACTGC CCCTCCCCCC TCCCCCGGAG CCAGGGAGTG GTTGGTGAAA 1440
GGGGGAGGCC AGCTGGAGAA CAAACGGGTA GTCAGGGGGT TGAGCGATTA GAGCCCTTGT 1500
ACCCTACCCA GGAATGGTTG GGGAGGAGGA GGAAGAGGTA GGAGGTAGGG GAGGGGGCGG 1560
GGTTTTGTCA CCTGTCACCT GCTCCGGCTG TGCCTAGGGC GGGCGGGCGG GGAGTGGGGG 1620
GACCGGTATA AAGCGGTAGG CGCCTGTGCC CGCTCC 1656

FIG. 7